Go Deep
Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,141 | -13.9 | 8.89 | 0.00 | 184.69 |
| Oct 2026 | 22,308 | -13.4 | 8.57 | 0.00 | 178.06 |
| Oct 2026 | 22,212 | -13.7 | 8.75 | 0.00 | 182.05 |
| Oct 2026 | 22,236 | -13.6 | 8.70 | 0.00 | 181.10 |
| Oct 2026 | 22,165 | -13.9 | 8.84 | 0.00 | 183.49 |
| Oct 2026 | 22,165 | -13.9 | 8.84 | 0.00 | 183.12 |
Polaryx Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -1,380,000.0 | -2,544,000.0 | -1,495,000.0 | -1,430,000.0 |
| EPS | -0.0 | -0.1 | — | -0.0 |
Polaryx Therapeutics, Inc. Revenue & Profit: Last 3 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| Net Profit | -8,985,000.0 | -30,356,000.0 | -3,779,000.0 |
| EPS | -0.2 | -0.6 | -0.1 |
Polaryx Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Total Assets | 5,170,000.0 | 5,001,000.0 | 2,315,000.0 |
| Total Liabilities | 605,000.0 | 289,000.0 | 1,038,000.0 |
| Total Equity | 4,565,000.0 | 4,712,000.0 | 1,277,000.0 |
Owes vs Owns
Polaryx Therapeutics, Inc. owed $0.07 for every $1 it owned in Jun 2026, down from $0.45 in Dec 2023.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.12× | 0.06× | 0.45× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Polaryx Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 99.5%Other assets 0.5%
How it's funded — Dec 2025
Payables 9.1%Other liabilities 2.6%Shareholders' equity 88.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | 5.1 | 4.6 | 0.0 |
| Receivables | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 |
| Other assets | 0.0 | 0.4 | 2.3 |
| Liabilities & equity | |||
| Short-term debt | 0.0 | 0.0 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.0 |
| Payables | 0.5 | 0.1 | 0.5 |
| Other liabilities | 0.1 | 0.2 | 0.4 |
| Shareholders' equity | 4.6 | 4.7 | 1.3 |
| Net tangible assets | 4.6 | 4.7 | 1.3 |
Polaryx Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Operating Activities | -3,944,000.0 | -2,573,000.0 | -173,000.0 |
| Financing Activities | 4,466,000.0 | 7,192,000.0 | 128,000.0 |